Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995 / Edition 1

Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995 / Edition 1

ISBN-10:
052162620X
ISBN-13:
9780521626200
Pub. Date:
08/13/1997
Publisher:
Cambridge University Press
ISBN-10:
052162620X
ISBN-13:
9780521626200
Pub. Date:
08/13/1997
Publisher:
Cambridge University Press
Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995 / Edition 1

Networks of Innovation: Vaccine Development at Merck, Sharp and Dohme, and Mulford, 1895-1995 / Edition 1

Paperback

$39.99
Current price is , Original price is $39.99. You
$39.99 
  • SHIP THIS ITEM
    Qualifies for Free Shipping
  • PICK UP IN STORE
    Check Availability at Nearby Stores
  • SHIP THIS ITEM

    Temporarily Out of Stock Online

    Please check back later for updated availability.


Overview

Networks of Innovation offers a historical perspective on the manner in which private sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp & Dohme, which acquired Mulford in 1929, and on Merck & Co., Inc., which merged with Sharp & Dohme in 1953. By surveying a century of innovation in biologicals, the authors show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad.

Product Details

ISBN-13: 9780521626200
Publisher: Cambridge University Press
Publication date: 08/13/1997
Series: Vaccine Development at Merck, Sharp and Dohme, and Mulford,
Edition description: Reprint, 1st Paperback Edition
Pages: 288
Product dimensions: 6.02(w) x 8.94(h) x 0.79(d)

Table of Contents

Preface; 1. 1894: 'The foremost medical question of the day'; 2. The Mulford story; 3. A Sharp & Dohme interlude; 4. The virology network and a new programme at Merck, Sharp & Dohme; 5. Hilleman's innovations: first phase, measles-mumps-rubella; 6. Dangerous interlude, Marek's Disease adjuvant 65, the Swine Flu drama; 7. Transforming bacteriology: a second phase, meningitis, pneumonia, haemophilus, influenzae; 8. New networks, new leadership: the Hepatitis B vaccines; 9. Vaccine innovation in the nineties: new strategies, new structures, and public confrontations; A word about sources.
From the B&N Reads Blog

Customer Reviews